Go Deep
Biofil Chemicals and Pharmaceuticals Limited
Biofil Chemicals and Pharmaceuticals Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Sep 2026 | 24,640 | 105.0 | 2.38 | 0.14 | 31.51 |
| Oct 2026 | 24,131 | 97.7 | 2.21 | 0.14 | 29.31 |
| Oct 2026 | 23,093 | 177.4 | 2.27 | 0.14 | 30.15 |
Biofil Chemicals and Pharmaceuticals Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 123,502,000.0 | 75,656,000.0 | 8,563,000.0 | 135,408,000.0 |
| Net Profit | 1,091,000.0 | 2,122,000.0 | 792,000.0 | 836,000.0 |
| EPS | 0.1 | 0.1 | 0.1 | 0.1 |
Biofil Chemicals and Pharmaceuticals Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 283,952,000.0 | 334,022,000.0 | 400,353,000.0 | 300,352,000.0 | — |
| Net Profit | 27,860,000.0 | 5,577,000.0 | 7,092,000.0 | 5,604,000.0 | — |
| EPS | 1.7 | 0.3 | 0.4 | 0.3 | — |
Biofil Chemicals and Pharmaceuticals Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 428,481,000.0 | 509,604,000.0 | 470,827,000.0 | 314,057,000.0 | — |
| Total Liabilities | 212,838,000.0 | 321,788,000.0 | 288,799,000.0 | 141,042,000.0 | — |
| Total Equity | 215,643,000.0 | 187,816,000.0 | 182,028,000.0 | 173,015,000.0 | — |
Owes vs Owns
Biofil Chemicals and Pharmaceuticals Limited owed ₹0.50 for every ₹1 it owned in Mar 2026, up from ₹0.45 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.50× | 0.63× | 0.61× | 0.45× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Biofil Chemicals and Pharmaceuticals Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 7.8%Receivables 64.4%Inventory 9.3%Fixed assets (tangible) 16.2%Other assets 2.3%
How it's funded — Mar 2026
Short-term debt 7.0%Payables 39.8%Other liabilities 2.8%Shareholders' equity 50.3%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 3.3 | 0.3 | 2.3 | 0.0 |
| Receivables | 27.6 | 38.3 | 33.0 | 20.5 |
| Inventory | 4.0 | 3.3 | 2.5 | 1.2 |
| Fixed assets (tangible) | 6.9 | 8.3 | 8.6 | 9.0 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 1.0 | 0.7 | 0.6 | 0.7 |
| Liabilities & equity | ||||
| Short-term debt | 3.0 | 0.5 | 0.4 | 0.5 |
| Long-term debt | 0.0 | 0.0 | 0.0 | 0.0 |
| Payables | 17.1 | 31.0 | 27.6 | 12.6 |
| Other liabilities | 1.2 | 0.7 | 0.9 | 0.9 |
| Shareholders' equity | 21.6 | 18.8 | 18.2 | 17.3 |
| Net tangible assets | 21.6 | 18.8 | 18.2 | 17.3 |
Biofil Chemicals and Pharmaceuticals Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | -6,049,000.0 | -19,237,000.0 | 23,937,000.0 | -1,118,000.0 | — |
| Investing Activities | 11,374,000.0 | -1,001,000.0 | -229,000.0 | -106,000.0 | — |
| Financing Activities | 25,386,000.0 | -45,000.0 | -1,249,000.0 | 151,000.0 | — |